XML 28 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Revenues
 12 Months Ended
Dec. 31, 2022
Revenues [Abstract]  
Revenues Revenues
Product Revenues
The Company’s net product revenues consisted of the following for the years ended December 31:
20222021
Products:
Kristalose$15,205,155 $15,993,658 
Sancuso13,205,603 — 
Vibativ7,487,462 11,704,062 
Caldolor4,827,200 4,970,301 
Acetadote501,040 850,993 
Omeclamox-Pak29,145 (388,657)
Vaprisol(447,697)1,859,581 
RediTrex(126,726)55,321 
Total net product revenues$40,681,182 $35,045,259 
Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
The international agreements provide for $1.5 million in non-refundable up-front payments, milestone payments of up to $2.4 million related to regulatory approvals and up to $5.6 million in payments related to product sales. From 2012 through December 31, 2022, the Company has recognized a cumulative $1.9 million in upfront payments as other revenue and has recognized $0.5 million during the year 2022.
Other revenues during 2022 and 2021 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2 million and $0.4 million for the years ending December 31, 2022 and 2021, respectively.